PCOC16: Panel Discussion on the Future of Oncology Care

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

The executive order targets lower drug prices through Medicare reforms, anticompetitive crackdowns, and transparency mandates.

While findings around hospital and emergency department use were similar at the individual and neighborhood levels, the use of outpatient services differed.